BIRC5 expression is a poor prognostic marker in Ewing sarcoma

Pediatric Blood and Cancer

Volumn 60, Issue 1, 2013, Pages 35-40

  Hingorani, Pooja ^a   Dickman, Paul ^a   Garcia Filion, Pamela ^a   White Collins, Andrea ^a   Kolb, Edward A ^b   Azorsa, David O ^c  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; BIRC5; Ewing sarcoma; Survivin; Targeted therapy

Indexed keywords

SEPANTRONIUM BROMIDE; SMALL INTERFERING RNA; SURVIVIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EWING SARCOMA; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; WESTERN BLOTTING;

ADOLESCENT; ADULT; APOPTOSIS; BIOLOGICAL MARKERS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NAPHTHOQUINONES; PROGNOSIS; SARCOMA, EWING;

EID: 84870174210     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24290     Document Type: Article

References (40)

1. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008; 20: 419-427.
2. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003; 22: 9282-9287.
3. Dalal S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005; 11: 2364-2378.
4. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
5. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-8589.
6. Vader G, Kauw JJ, Medema RH, et al. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 2006; 7: 85-92.
7. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
8. Park DS, Hwang KE, Shim H, et al. Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions. Clin Exp Metastasis 2012; 29: 83-89.
9. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
10. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58: 5071-5074.
11. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002; 20: 1063-1068.
12. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113: 1076-1081.
13. Miller MA, Ohashi K, Zhu X, et al. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: A report from the children's oncology group. J Pediatr Hematol Oncol 2006; 28: 412-417.
14. Kappler M, Kotzsch M, Bartel F, et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 2003; 9: 1098-1104.
15. Okamoto K, Okamoto I, Okamoto W, et al. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res 70: 10402-10410.
16. Yamanaka K, Nakata M, Kaneko N, et al. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol 39: 569-575.
17. Azorsa DO, Gonzales IM, Basu GD, et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009; 7: 43.
18. Ohali A, Avigad S, Zaizov R, et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004; 23: 8997-9006.
19. Ferreira BI, Alonso J, Carrillo J, et al. Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene 2008; 27: 2084-2090.
20. Schaefer KL, Eisenacher M, Braun Y, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008; 44: 699-709.
21. Nakahara T, Kita A, Yamanaka K, et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 102: 614-621.
22. Wang Q, Chen Z, Diao X, et al. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells. Cancer Lett 302: 29-36.
23. Ryan BM, O'Donovan N, Duffy MJ. Survivin: A new target for anti-cancer therapy. Cancer Treat Rev 2009; 35: 553-562.
24. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344: 305-311.
25. Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001; 91: 2026-2032.
26. O'Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-398.
27. Lechler P, Renkawitz T, Campean V, et al. The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer 11: 120.
28. Speletas M, Argentou N, Karanikas V, et al. Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses. Clin Immunol 139: 155-163.
29. Rodel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65: 4881-4887.
30. Trabulo S, Cardoso AM, Santos-Ferreira T, et al. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharm 8: 1120-1131.
31. Zou J, Gan M, Mao N, et al. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin. Arch Med Res 41: 162-169.
32. Khan Z, Khan N, Tiwari RP, et al. Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 96: 267-273.
33. Satoh T, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3872-3880.
34. Lewis KD, Samlowski W, Ward J, et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 29: 161-166.
35. Giaccone G, Zatloukal P, Roubec J, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27: 4481-4486.
36. Yamanaka K, Nakahara T, Yamauchi T, et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 17: 5423-5431.
37. Tanioka M, Nokihara H, Yamamoto N, et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 68: 505-511.
38. Casati C, Dalerba P, Rivoltini L, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003; 63: 4507-4515.
39. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19.
40. Block MS, Suman VJ, Nevala WK, et al. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res 21: 438-445.